Journal of Neuro-Oncology

, Volume 80, Issue 1, pp 57–61 | Cite as

Complications of a temozolomide overdose: a case report

  • Alexander M. SpenceEmail author
  • Hans-Peter Kiem
  • Sonia Partap
  • Scott Schuetze
  • John R. Silber
  • Richard A. Peterson
Clinical–Patient Studies


Purpose and background

This is a report of a 53 year-old man with a glioblastoma multiforme (GBM) treated with an excessive dose of temozolomide (TMZ).


This is a single case review of all clinically relevant records. O 6-methylguanine-DNA methyltransferase activity was determined by a biochemical assay.


Following conventional radiotherapy (RT) without concurrent chemotherapy, the patient received 5,500 mg of TMZ over 2 days. At the standard dose of 200 mg/m2/day his total 5-day dose should have been 1,940 mg. Acutely he had nausea, vomiting and diarrhea for 2 days which cleared. The dominant severe toxicity was pancytopenia between one and four weeks after TMZ which was complicated by secondary infections that were successfully managed. Transient transaminitis occurred but there were no significant pulmonary, renal or other systemic toxicities. His progression free survival was 22 months and overall survival 24 months.


His outcome suggests that TMZ may prove to be a good agent for dose-escalation trials with hematopoietic stem cell rescue.


Glioblastoma multiforme Temozolomide Overdose Toxicity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Silber JR, Blank A, Bobola MS, Ghatan S, Kolstoe DD, Berger MS (1999) O 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res 5:807–814PubMedGoogle Scholar
  2. 2.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003PubMedCrossRefGoogle Scholar
  3. 3.
    Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS, Quarterman CP, Hoffman R, Stevens MF, Brampton MH, Gibson AC (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65:287–291PubMedGoogle Scholar
  4. 4.
    Newlands ES, Oȁ9Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A:2236–2241PubMedCrossRefGoogle Scholar
  5. 5.
    Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP (1993) Depletion of O 6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 67:1299–1302PubMedGoogle Scholar
  6. 6.
    Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treatment Rev 23:35–61CrossRefGoogle Scholar
  7. 7.
    Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ (1997) Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3:1093–1100PubMedGoogle Scholar
  8. 8.
    Rudek MA, Donehower RC, Statkevich P, Batra VK, Cutler DL, Baker SD (2004) Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. Pharmacotherapy 24:16–25PubMedCrossRefGoogle Scholar
  9. 9.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRefGoogle Scholar
  10. 10.
    Bobola MS, Tseng SH, Blank A, Berger MS, Silber JR (1996) Role of O 6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 2:735–741PubMedGoogle Scholar
  11. 11.
    Kokkinakis DM, Bocangel DB, Schold SC, Moschel RC, Pegg AE (2001) Thresholds of O 6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide. Clin Cancer Res 7:421–428PubMedGoogle Scholar
  12. 12.
    Esteller M (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21:5427–5440PubMedCrossRefGoogle Scholar
  13. 13.
    Brandes AA, Palmisano V, Pasetto LM, Basso U, Monfardini S (2001) High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. Cancer Invest 19:41–48PubMedCrossRefGoogle Scholar
  14. 14.
    Durando X, Lemaire JJ, Tortochaux J, Van-Praagh I, Kwiatkowski F, Vincent C, Bailly C, Verrelle P, Irthum B, Chazal J, Bay JO (2003) High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant 31:559–564PubMedCrossRefGoogle Scholar
  15. 15.
    Fine HA, Antman KH (1992) High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience. Bone Marrow Transplant 10:315–321PubMedGoogle Scholar
  16. 16.
    Mbidde EK, Selby PJ, Perren TJ, Dearnaley DP, Whitton A, Ashley S, Workman P, Bloom HJ, McElwain TJ (1988) High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer 58:779–782PubMedGoogle Scholar
  17. 17.
    Adkins DR, Irvin R, Kuhn J, Boldt DH, Roodman GD, Salzman D, Freytes C, Von Hoff DD, LeMaistre CF (1993) A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. Invest New Drugs 11:169–179PubMedCrossRefGoogle Scholar
  18. 18.
    Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE II, Bigner DD,␣Friedman HS (2005) Phase I trial of temozolomide plus O 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23:7178–7187PubMedCrossRefGoogle Scholar
  19. 19.
    Neff T, Beard BC, Peterson LJ, Anandakumar P, Thompson J, Kiem HP (2005) Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 105:997–1002PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2006

Authors and Affiliations

  • Alexander M. Spence
    • 1
    Email author
  • Hans-Peter Kiem
    • 2
  • Sonia Partap
    • 1
  • Scott Schuetze
    • 2
  • John R. Silber
    • 3
  • Richard A. Peterson
    • 1
  1. 1.Department of NeurologyUniversity of Washington School of MedicineSeattleUSA
  2. 2.Department of Medicine (Medical Oncology)University of Washington School of MedicineSeattleUSA
  3. 3.Department of NeurosurgeryUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations